[go: up one dir, main page]

PE20180659A1 - Peptidos lipidados resistentes a proteasas - Google Patents

Peptidos lipidados resistentes a proteasas

Info

Publication number
PE20180659A1
PE20180659A1 PE2017002540A PE2017002540A PE20180659A1 PE 20180659 A1 PE20180659 A1 PE 20180659A1 PE 2017002540 A PE2017002540 A PE 2017002540A PE 2017002540 A PE2017002540 A PE 2017002540A PE 20180659 A1 PE20180659 A1 PE 20180659A1
Authority
PE
Peru
Prior art keywords
peptides
proteases
protease resistant
lipid peptides
methods
Prior art date
Application number
PE2017002540A
Other languages
English (en)
Inventor
Jefferson D Revell
Maria A Bednarek
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of PE20180659A1 publication Critical patent/PE20180659A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invencion proporciona peptidos resistentes a proteasas, metodos de preparacion de tales peptidos, asi como composiciones que comprenden peptidos resistentes a proteasas y metodos de tratamiento que utilizan tales peptidos. Una combinacion de determinados residuos de aminoacidos y sustitucion de aminoacidos funcionalizados con alfa-metilo en lugar de aminoacidos naturales para producir peptidos resistentes a proteasas.
PE2017002540A 2015-06-10 2016-06-09 Peptidos lipidados resistentes a proteasas PE20180659A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173631P 2015-06-10 2015-06-10
US201662343390P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
PE20180659A1 true PE20180659A1 (es) 2018-04-17

Family

ID=56235790

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002540A PE20180659A1 (es) 2015-06-10 2016-06-09 Peptidos lipidados resistentes a proteasas

Country Status (25)

Country Link
US (3) US10414811B2 (es)
EP (2) EP3865504A1 (es)
JP (1) JP6811190B2 (es)
KR (1) KR20180016441A (es)
CN (1) CN108271373B (es)
AU (2) AU2016277449B2 (es)
CA (1) CA2988841C (es)
CL (1) CL2017003144A1 (es)
CO (1) CO2017012675A2 (es)
CR (1) CR20170559A (es)
DO (1) DOP2017000287A (es)
EA (1) EA036415B1 (es)
ES (1) ES2849950T3 (es)
IL (1) IL255978B (es)
MX (1) MX389407B (es)
MY (1) MY185816A (es)
NI (1) NI201700156A (es)
NZ (1) NZ738909A (es)
PE (1) PE20180659A1 (es)
PH (1) PH12017502259A1 (es)
SG (1) SG10201911837SA (es)
SV (1) SV2017005585A (es)
TN (1) TN2017000519A1 (es)
TW (1) TWI726889B (es)
WO (1) WO2016198544A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190017017A (ko) * 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
PE20210116A1 (es) * 2017-10-31 2021-01-19 Medimmune Ltd Administracion oral de analogos del peptido glp-1
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4259647A4 (en) 2021-09-15 2025-03-26 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
WO2004022004A2 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
CN101262874A (zh) * 2005-09-08 2008-09-10 塔夫茨大学信托人 稳定化的glp-1类似物
EP1854455B1 (en) * 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
AU2008266448B2 (en) 2007-06-21 2013-06-13 Technische Universitat Munchen Biological active proteins having increased in vivo and/or vitro stability
JP5270687B2 (ja) 2007-12-11 2013-08-21 カディラ ヘルスケア リミティド グルカゴンアンタゴニスト活性及びｇｌｐ−１アゴニスト活性を有するペプチド模倣体
US8685895B2 (en) * 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
CN103079587B (zh) 2010-05-13 2016-05-11 印第安纳大学研究及科技有限公司 呈现核激素受体活性的胰高血糖素超家族肽
US20130143800A1 (en) 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
WO2014088631A1 (en) 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
EP3238734A1 (en) * 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
JP2017502003A (ja) 2013-12-13 2017-01-19 メディミューン リミテッド プロテアーゼ耐性ペプチド

Also Published As

Publication number Publication date
US20210221866A1 (en) 2021-07-22
TWI726889B (zh) 2021-05-11
EA201792640A1 (ru) 2018-06-29
TW201710287A (zh) 2017-03-16
NI201700156A (es) 2018-10-18
WO2016198544A1 (en) 2016-12-15
MX389407B (es) 2025-03-20
EA036415B1 (ru) 2020-11-09
JP6811190B2 (ja) 2021-01-13
EP3865504A1 (en) 2021-08-18
US20180162920A1 (en) 2018-06-14
US10414811B2 (en) 2019-09-17
AU2016277449B2 (en) 2019-06-20
SV2017005585A (es) 2018-05-22
US20200079833A1 (en) 2020-03-12
JP2018518485A (ja) 2018-07-12
CA2988841A1 (en) 2016-12-15
EP3307769A1 (en) 2018-04-18
KR20180016441A (ko) 2018-02-14
CA2988841C (en) 2023-06-06
CR20170559A (es) 2018-05-11
CN108271373B (zh) 2021-12-28
NZ738909A (en) 2019-08-30
MY185816A (en) 2021-06-10
IL255978A (en) 2018-01-31
CN108271373A (zh) 2018-07-10
MX2017015482A (es) 2018-02-09
DOP2017000287A (es) 2018-04-15
CO2017012675A2 (es) 2018-02-28
TN2017000519A1 (en) 2019-04-12
PH12017502259A1 (en) 2018-06-25
EP3307769B1 (en) 2020-12-02
ES2849950T3 (es) 2021-08-24
SG10201911837SA (en) 2020-01-30
IL255978B (en) 2021-04-29
CL2017003144A1 (es) 2018-04-13
AU2016277449A1 (en) 2018-02-01
AU2019229424A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
NI201700156A (es) Péptidos lipidados resistentes a proteasas
MX2019011764A (es) Composiciones limpiadoras y usos de las mismas.
MX2016013034A (es) Composicion detergente.
UY36578A (es) Proteínas de unión a tslp
MX2018004683A (es) Composicion detergente que comprende variantes de amilasa y proteasa.
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
BR112016005286A2 (pt) composições e métodos compreendendo variantes de protease do clado lg12
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
MX2017007554A (es) Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa.
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
SG10201805039UA (en) Protease resistant peptides
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX2016010838A (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
MX386458B (es) Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales.
NZ744289A (en) Composition containing amino acids
EA201990181A1 (ru) Получение активированных клостридиальных нейротоксинов
MX375918B (es) Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis.
PE20180574A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
BR112018074923A2 (pt) composição cosmética antissinais, uso da composição e método para tratamento antissinais